Barely Significant
← all excerpts

Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study).

BMC Cancer · 2021 · PMC8381542 · PMID 34425776

Europe PMCDOI
1
hedged sentence
—
closest p
—
boldest claim

The sentences

showed a trendno p-value reported
A phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab or cetuximab for patients with KRAS wild-type untreated mCRC (CALGB/SWOG80405), in which the primary endpoint was OS, showed no significant difference in the combination of chemotherapy with cetuximab or bevacizumab, but it showed a trend toward longer OS in cetuximab-treated patients versus bevacizumab-treated patients with FOLFOX [ 5 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.